MODIFIED Discovery of Potent anti-Mpro Inhibitors for Covid-19 Treatment using Alpha-ketoamide Derivatives
Next-gen Mpro inhibitors with improved potency and pharmacology.
Researchers at Purdue University have developed a new class of compounds that target the main protease (Mpro) in SARS-COV-2/Covid-19 infection.
With the world facing the coronavirus (Covid-19) pandemic, there is an immediate need for intensive protection from the severe acute respiratory illness associated with the disease. Currently, there is no effective pharmaceutical treatment available for SARS-COV-2 infection. These compounds developed by Purdue University researchers are newer modified versions of previous alpha-ketoamide derivatives that have shown potency as anti-viral agents against Covid-19. One of the compounds identified showed potent activity (IC50= 4.2micromolar) in SARS-COV-2 infected Vero-E6 cells.
Advantages:
-Excellent Antiviral Activity Against SARS-CoV-2 in Mammalian Cells
-Improved Drug-Like Properties
Potential Applications:
-Treatment of Covid-19
-Treatment of Coronavirus
-Pharmaceutical Research & Development
Technology Validation: The compounds have been validated in Vero-E6 cells.
Recent Publication:
"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication"
Nature Communication
DOI: 10.1038/s41467-021-20900-6
TRL: Pharmaceuticals
Intellectual Property:
NATL-Patent, N/A, Canada
Provisional-Gov. Funding, 2020-12-01, United States
NATL-Patent, 2021-11-30, Europe
NATL-Patent, 2021-11-30, Canada
PCT-Gov. Funding, 2021-11-30, WO
NATL-Patent, 2023-05-31, United States
Keywords: Chemistry and Chemical Analysis, Coronavirus, COVID-19, Inhibitors, Medicinal Chemistry, Pharmaceuticals, Protease Inhibitor